|Bid||2.0400 x 1100|
|Ask||2.6000 x 1200|
|Day's Range||2.1000 - 2.3035|
|52 Week Range||1.8900 - 7.5100|
|Beta (5Y Monthly)||0.29|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 07, 2022 - Mar 11, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced that its product portfolio of FDA-approved brands delivered combined revenues of $10.3 million during the second quarter of 2022 – a 14% increase over the prior year period. Cumberland also reports a 10% increase in net revenues for the first half of the year compared to the same period in 2021.
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today released its 2021 Sustainability Report detailing its activities regarding its involvement in environmental, social and governance matters.
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that it will release its second quarter 2022 financial results and provide a company update after the market closes on Tuesday, Aug. 9, 2022.